⌘K
t
| TIDM | CIZ |
| Share Price | Loading... |
| Market Cap | Loading... |
Cizzle Biotechnology Holdings plc provided an update on 3 October 2024 regarding its strategic and exclusive licensing partnership agreement for North America with Cizzle Bio Inc (BIO). The Company signed a Memorandum of Understanding (MoU) with BIO on 2 April 2024, which was extended for 60 days on 25 July 2024, concerning the marketing of its CIZ1B biomarker. Additionally, BIO announced a collaboration with Moffitt Cancer Center on 9 September 2024, to test patients with suspicious lung nodules.
| Date | 3 Oct 2024 |
| Time | 13:12:12 |
| Category | Corporate updates |
| ID | 8688G |
3 October 2024
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Further Update on Strategic Licensing and Partnership Agreement for North America
Cizzle Biotechnology, the UK based diagnostics developer, today provides a further update on progress with the Company's planned strategic and exclusive licensing partner in the USA, Cizzle Bio Inc ("BIO").
Following the Company's signing of a memorandum of understanding ("MoU") with BIO announced on 2 April 2024 and the 60 day extension to finalise a full and binding license agreement (the "Agreement") announced on 25 July 2024, the Company has continued to support BIO's plans to market the Company's CIZ1B biomarker and to complete the Agreement. The final details of the Agreement are expected to be completed shortly, at which time the Company will make a further announcement.
In the meantime, BIO continues to attract significant clinical interest to build on the recent collaboration with Moffitt Cancer Center, the number one cancer hospital in Florida and the Southeast USA, to test patients with suspicious lung nodules, as announced on 9 September 2024.
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 3328 5656 |
|
John Depasquale/George Payne (Corporate Finance) |
|
|
Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking) |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6630 |
|
|
Tim Metcalfe |
|
|
|
Florence Chandler |
|
|
About Cizzle Biotechnology
Cizzle is developing a blood test to help in the early detection of lung cancer. Based on the pioneering work of Professor Coverley and colleagues, at the University of York, on a naturally occurring cell nuclear protein involved in DNA replication called CIZ1, they discovered that a variant called CIZ1B is highly associated with the presence of early-stage cancer. The company has now entered into commercial royalty bearing licensing agreements and collaborations with leading centres of excellence in cancer for the use of its proprietary technology as part of its strategy to bring its non-intrusive, cost-effective blood test to market. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
About Cizzle Bio Inc
Cizzle Bio Inc, a company registered in Texas USA, stands at the forefront of biotechnological innovation, dedicated to revolutionizing the detection of lung cancer through groundbreaking diagnostic tools. With exclusive rights to detect the CIZ1B Biomarker in the USA and Canada, we are driven by a commitment to improve early cancer detection and enhance patient outcomes.